

Inhalation anaesthesia

Inhalation anaesthesia is one of the options for general anaesthesia. To achieve it, inhalation (*volatile*) anesthetics, so-called anesthetic gases, are used, which are substances that are redistributed throughout the body after inhalation into the lungs, and their main target is the brain.

Inhalation anesthetics

Inhalation anesthetics are generally referred to as gases, but this is not a completely accurate designation. As such, the gases are only nitrous oxide and xenon. Other anesthetics are in liquid form, so it is first necessary to convert them into a volatile form using special vaporizers. It was possible to define the properties of a hypothetical ideal inhalation anesthetic, which, however, the substances used so far do not fulfill 100%. This **ideal anesthetic** should meet the following conditions:

- quick and pleasant falling asleep and waking up,
- good controllability of the effect and the possibility of quickly changing the depth of anesthesia,
- sufficient analgesic effect,
- attenuation of reflexes and induction of myorelaxation,
- sufficient safety width,
- no toxic effects at clinical doses.

As has been said, no inhaled anesthetic in use yet meets all the mentioned conditions. For that reason, we usually *'combine* these substances with drugs from other groups, namely with intravenous anesthetics for rapid induction, opioids and nitrous oxide to enhance analgesia and muscle relaxants for complete muscle relaxation. In addition, the combination with other substances reduces the side and unwanted effects of volatile anesthetics.

Properties of volatile anesthetics

Volatile anesthetics allow relatively **easy controllability of the depth of anesthesia**. **Among their disadvantages, compared to intravenous ones, are the longer introduction' to anesthesia and the longer awakening**. This is due to the necessity of gas exchange in the lungs and their solubility. The higher the solubility of the anesthetic in the blood, the slower the induction and awakening, and vice versa. The magnitude of the effect is the so-called *minimum alveolar concentration* (MAC). MAC is defined as the alveolar concentration at which 50% of patients do not respond to skin incision with defensive movements. The MAC value is different for different anesthetics. It is true that the lower the MAC value, the more effective the anesthetic. However, other factors also influence this value.

The **MAC (and thus the need for anesthetic) decreases**:

- with increasing age,
- with hypothermia,
- during pregnancy,
- after premedication with opioids and during administration of opioids during anesthesia,
- with simultaneous use of sedative-hypnotics and i.v. anesthetic,
- with severe hypoxia ($\text{paO}_2 < 4.0 \text{ kPa}$), anemia and hypotension.

On the contrary **MAC rises**:

- with chronic alcohol abuse (does not apply to acute alcohol consumption),
- with fever,
- when addicted to opioids,
- with hyperthyroidism.

Individual volatile anesthetics

Halothane

Halothane was the first effective and non-explosive inhalation anesthetic in 1956, when it began to be used clinically. However, it is no longer **used** in common clinical practice.

Isoflurane

Isoflurane is a non-flammable, colorless and clear liquid that smells like ether. This substance has a very *low blood/gas partition coefficient*, from which the advantage of rapid induction of anesthesia would flow. However, this advantage is somewhat offset by the fact that inhalation of isoflurane causes **respiratory depression, breath holding, and respiratory tract irritation**. It is therefore not suitable for induction of anesthesia by inhalation, some of the i.v. anesthetic.

We determine the depth of anesthesia mainly according to blood pressure values, especially systolic. At the beginning of anesthesia, it is important to remember that BP values can drop significantly, even if we have not yet achieved a sufficiently deep anesthesia. We turn off the isoflurane approximately when the surgeons begin to sew the skin, after several hours of operation it takes about 10 minutes before the patient begins to open his eyes.

Sevoflurane

Sevoflurane is a non-flammable, colorless liquid with a slight odor of ether, slightly soluble in fats. Its blood/gas distribution coefficient is the lowest after **desflurane**, which leads to a very rapid increase in its concentration in the body and therefore to a **rapid introduction** to anesthesia. Good controllability of the depth of anesthesia and quick withdrawal are also related to this. In addition, there is no such irritation of the respiratory tract, so it is also suitable for **inhalation introduction**, e.g. in children.

A possible disadvantage of sevoflurane is the release of **inorganic fluoride** contained in its molecule. Inorganic fluoride is nephrotoxic, however, the threshold value for its nephrotoxicity in the case of sevoflurane is not defined. Another potential risk is the formation of compound A (*Compound A*), which occurs when in contact with soda lime. Although possible nephrotoxicity in humans has not been verified, in the USA, for example, sevoflurane is allowed only with a fresh gas flow of at least 2 l/min, but in other countries there are no restrictions for low-flow and minimal-flow anesthesia with this substance.

Desflurane

Desflurane is chemically very similar to isoflurane, it has a fluorine atom instead of a chlorine atom. For that reason, it has a much less harmful effect on the ozone layer. It is a non-flammable and non-explosive clear liquid with a pungent and irritating odor. It has the lowest boiling point of all volatile anesthetics (22.8 °C), therefore a **special vaporizer** is required for its use. Of all inhalational anesthetics, desflurane has the fastest induction and removal from anesthesia, as well as the most prompt controllability of the effect. Compared to the others, however, it has the weakest effect. Its disadvantage is also its higher price

Xenon

Xenon is a rare, inert, non-irritating gas without color and odor, which would have great positives for use in anesthesia. It has the fastest onset and withdrawal, there are no hemodynamic fluctuations, it has an analgesic effect, it has no mutagenic and teratogenic properties and it does not trigger malignant hyperthermia. Since 1990, however, it is still the subject of clinical studies. It is administered in a mixture with oxygen in a volume ratio of 70% xenon and 30% oxygen. Its **availability is currently minimal** due to its high price and as yet unproven cost-effective anesthetic systems and recycling that could reduce its consumption.

Low-flow and minimal-flow anesthesia

It is a technique of inhalation anesthesia in which there is only a **low input of fresh gases**. It is used in semi-closed systems, when the supply of fresh gases, i.e. usually oxygen and nitrous oxide, is reduced to 1 l/min at "low-flow" or 0.5 l/min during *minimal-flow* anesthesia.

Compared to anesthesia with normal fresh gas flows, it has several advantages:

- consumption is reduced and the use of volatile anesthetics becomes more efficient,
- reduction of emissions of inhalation anesthetics and nitrous oxide,
- higher humidity and temperature of inhaled gases.

Its administration, however, requires greater experience of the anesthesiologist.

Links

Related Articles

- Intravenous anesthetics
- General anesthesia
- Local anesthetics
- Regional anesthesia

References

- LARSEN, Reinhard. *Anesthesia*. 7th (2nd Czech) edition. Prague : Grada, 2004. 1376 pp. ISBN 80-247-0476-5.
- MÁLEK, J. - DVOŘÁK, A., et al. *Fundamentals of Anesthesiology* [online]. [cit. 2017-11-08]. <<https://www.lf3.cuni.cz/cs/pracoviste/anesteziologie/vyuka/studijni-materialy/zaklady-anesteziologie/>>.
- BARASH, G.Paul - CULLEN, F. Bruce - STOELTING, K. Robert, et al. *Clinical Anesthesiology*. 6. edition. 2015. 816 pp. ISBN 978-80-247-4053-9.